Sanofi Files New Pompe Hope Avalglucosidase Alfa In EU
Review Is Standard, Not Accelerated As Requested
The French drugmaker is looking to consolidate its dominance of the Pompe disease area by filing its successor to Myozyme in Europe, but Amicus Therapeutics' potential rival AT-GAA is on the horizon.
